Breaking News

Spectrum Appoints COO

April 21, 2014

Turgeon brings more than 30 years of experience to his new role

Joseph Turgeon has been promoted to president and chief operating officer at Spectrum Pharmaceuticals. Also, Thomas Riga will take over for Mr. Turgeon as senior vice president, chief commercial officer. Mr. Riga previously served as vice president, corporate accounts.

Mr. Turgeon joined the company in October 2012 and has more than 30 years of pharmaceutical sales experience. Prior to joining the company, he spent 22 years in various executive leadership roles at Amgen, most recently as vice president, sales, where he built and led the sales organization across multiple therapeutic areas.

“We are fortunate to have an experienced, passionate, and inspiring leader like Joe Turgeon spearhead the company,” said Rajesh C. Shrotriya, MD, chairman and chief executive officer of Spectrum Pharmaceuticals. “Joe was responsible for building a top sales organization and for launching four of the world’s top-selling biologics, during his over two decades at Amgen. With a rare depth of experience in the biotechnology industry, a keen understanding of our business, and very strong leadership skills, Joe is uniquely qualified for this position. He has been instrumental in helping Spectrum execute our strategy since he joined us in 2012. With multiple launches and NDAs planned in the coming years, I believe Joe’s leadership is exactly what Spectrum needs to become a leader in hematology/oncology.”

Mr. Riga has more than 15 years of pharmaceutical sales and management experience having held various positions at Amgen, Eli Lilly, and Dendreon. Since joining Spectrum, Mr. Riga has been instrumental in the reorganization of the corporate accounts function, and successful partnerships and renegotiations with partners. 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks